AGR2 and prostate carcinoma: [51] found that AGR2 directly interacts with VEGFA and enhances VEGFR/VEGFR2 signaling in prostate cancer cells, leading to the acquisition of a mesenchymal phenotype in vivo and in vitro, which is associated with increased invasiveness and metastatic growths.